Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q8IXI2

UPID:
MIRO1_HUMAN

ALTERNATIVE NAMES:
Rac-GTP-binding protein-like protein; Ras homolog gene family member T1

ALTERNATIVE UPACC:
Q8IXI2; A4FVB6; A6NFV0; B4DG48; J9JIH9; Q6NUR3; Q6P9F8; Q6PJG1; Q6YMW8; Q86UB0; Q8IW28; Q8IXJ7; Q9H067; Q9H9N8; Q9NUZ2

BACKGROUND:
The protein Mitochondrial Rho GTPase 1, with alternative names Rac-GTP-binding protein-like protein and Ras homolog gene family member T1, is a mitochondrial GTPase involved in mitochondrial trafficking. It regulates anterograde transport and subcellular distribution of mitochondria, and is key in promoting mitochondrial fission in response to high calcium levels. This protein's function is essential for maintaining mitochondrial integrity and dynamics.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Mitochondrial Rho GTPase 1 offers a pathway to uncovering novel therapeutic approaches. Given its critical role in mitochondrial trafficking and fission, targeting this protein could lead to innovative treatments for diseases linked to mitochondrial dysfunction.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.